AG˹ٷ

STOCK TITAN

[8-K] ADTRAN Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) has filed a Form 144 to notify the SEC of an intended insider sale.

  • Shares to be sold: 64,508 common shares
  • Aggregate market value: $1,928,595.68
  • Approximate sale date: 07/30/2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Shares outstanding: 74,107,668

The shares were acquired the same day (07/30/2025) through the exercise of employee stock options under a registered plan and will be sold for cash. No other sales by this insider were reported in the past three months.

The proposed disposition equals roughly 0.09% of total shares outstanding, indicating a modest, routine-sized transaction rather than a large liquidation. The filer attests to having no undisclosed material adverse information and confirms compliance with Rule 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentato un Modulo 144 per notificare alla SEC una vendita interna prevista.

  • Azioni da vendere: 64.508 azioni ordinarie
  • Valore di mercato complessivo: 1.928.595,68 $
  • Data approssimativa della vendita: 30/07/2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Azioni in circolazione: 74.107.668

Le azioni sono state acquisite lo stesso giorno (30/07/2025) tramite l'esercizio di opzioni azionarie per dipendenti nell'ambito di un piano registrato e saranno vendute per contanti. Nessun'altra vendita da parte di questo insider è stata segnalata negli ultimi tre mesi.

La cessione proposta corrisponde a circa il 0,09% del totale delle azioni in circolazione, indicando una transazione modesta e di dimensioni ordinarie, piuttosto che una liquidazione importante. Il dichiarante attesta di non possedere informazioni materiali negative non divulgate e conferma la conformità alla Regola 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentado un Formulario 144 para notificar a la SEC sobre una venta interna prevista.

  • Acciones a vender: 64,508 acciones ordinarias
  • Valor de mercado agregado: 1,928,595.68 $
  • Fecha aproximada de venta: 30/07/2025
  • Corredor: Morgan Stanley Smith Barney LLC, Nueva York
  • Acciones en circulación: 74,107,668

Las acciones fueron adquiridas el mismo día (30/07/2025) mediante el ejercicio de opciones sobre acciones para empleados bajo un plan registrado y serán vendidas por efectivo. No se reportaron otras ventas por parte de este insider en los últimos tres meses.

La disposición propuesta equivale aproximadamente al 0.09% del total de acciones en circulación, indicando una transacción modesta y rutinaria en lugar de una liquidación grande. El declarante certifica no poseer información material adversa no divulgada y confirma el cumplimiento con la Regla 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA)� 내부� 매도� 알리� 위해 Form 144� SEC� 제출했습니다.

  • 판매 예정 주식 �: 64,508 보통�
  • � 시장 가�: $1,928,595.68
  • 예상 매도�: 2025� 7� 30�
  • 중개�: Morgan Stanley Smith Barney LLC, 뉴욕
  • 발행 주식 총수: 74,107,668

주식읶 동일� �(2025� 7� 30�) 직원 주식매수선택� 행사� 취득되었으며, 현금으로 매도� 예정입니�. 지� 3개월� 해당 내부자의 다른 매도 보고� 없었습니�.

이번 매도 예정 주식읶 전체 발행 주식� � 0.09%� 해당하며, 대규모 청산보다� 소규� 일상적인 거래임을 나타냅니�. 제출자는 미공� 중대� 불리� 정보가 없음� 증명하며, Rule 10b5-1 준수를 확인합니�.

Kiniksa Pharmaceuticals International, plc (KNSA) a déposé un Formulaire 144 pour informer la SEC d'une vente d'initié prévue.

  • Actions à vendre : 64 508 actions ordinaires
  • Valeur marchande totale : 1 928 595,68 $
  • Date approximative de la vente : 30/07/2025
  • Intermédiaire : Morgan Stanley Smith Barney LLC, New York
  • Actions en circulation : 74 107 668

Les actions ont été acquises le même jour (30/07/2025) par l'exercice d'options d'achat d'actions des employés dans le cadre d'un plan enregistré et seront vendues contre espèces. Aucune autre vente par cet initié n'a été signalée au cours des trois derniers mois.

La cession proposée représente environ 0,09 % du total des actions en circulation, indiquant une transaction modeste et de taille courante plutôt qu'une liquidation importante. Le déclarant atteste ne pas disposer d'informations défavorables matérielles non divulguées et confirme sa conformité à la règle 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) hat ein Formular 144 eingereicht, um die SEC über einen geplanten Insider-Verkauf zu informieren.

  • Zu verkaufende Aktien: 64.508 Stammaktien
  • Gesamtmarktwert: 1.928.595,68 $
  • Ungefähres Verkaufsdatum: 30.07.2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Ausstehende Aktien: 74.107.668

Die Aktien wurden am selben Tag (30.07.2025) durch Ausübung von Mitarbeiteraktienoptionen im Rahmen eines registrierten Plans erworben und werden gegen Bargeld verkauft. In den letzten drei Monaten wurden keine weiteren Verkäufe dieses Insiders gemeldet.

Die geplante Veräußerung entspricht etwa 0,09 % der insgesamt ausstehenden Aktien und deutet auf eine eher kleine, routinemäßige Transaktion statt auf eine große Liquidation hin. Der Einreicher bestätigt, keine nicht offengelegten wesentlichen nachteiligen Informationen zu besitzen und die Einhaltung von Regel 10b5-1 sicherzustellen.

Positive
  • None.
Negative
  • Insider plans to sell 64,508 shares (~0.09% of 74.1 M outstanding) valued at $1.93 M

Insights

TL;DR: Small insider sale (0.09% OS) worth $1.9 M; signals routine diversification, limited fundamental impact.

The Form 144 shows an insider intends to sell 64,508 newly-exercised option shares, worth about $1.93 million, through Morgan Stanley on 07/30/2025. Given 74.1 million shares outstanding, the sale is immaterial to float and does not suggest broad insider pessimism. Lack of prior 3-month sales and same-day option exercise point to liquidity/tax planning rather than a directional bet. Investors typically view such filings as neutral unless accompanied by larger cluster selling. I rate the filing neutral for valuation and trading outlook.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentato un Modulo 144 per notificare alla SEC una vendita interna prevista.

  • Azioni da vendere: 64.508 azioni ordinarie
  • Valore di mercato complessivo: 1.928.595,68 $
  • Data approssimativa della vendita: 30/07/2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Azioni in circolazione: 74.107.668

Le azioni sono state acquisite lo stesso giorno (30/07/2025) tramite l'esercizio di opzioni azionarie per dipendenti nell'ambito di un piano registrato e saranno vendute per contanti. Nessun'altra vendita da parte di questo insider è stata segnalata negli ultimi tre mesi.

La cessione proposta corrisponde a circa il 0,09% del totale delle azioni in circolazione, indicando una transazione modesta e di dimensioni ordinarie, piuttosto che una liquidazione importante. Il dichiarante attesta di non possedere informazioni materiali negative non divulgate e conferma la conformità alla Regola 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentado un Formulario 144 para notificar a la SEC sobre una venta interna prevista.

  • Acciones a vender: 64,508 acciones ordinarias
  • Valor de mercado agregado: 1,928,595.68 $
  • Fecha aproximada de venta: 30/07/2025
  • Corredor: Morgan Stanley Smith Barney LLC, Nueva York
  • Acciones en circulación: 74,107,668

Las acciones fueron adquiridas el mismo día (30/07/2025) mediante el ejercicio de opciones sobre acciones para empleados bajo un plan registrado y serán vendidas por efectivo. No se reportaron otras ventas por parte de este insider en los últimos tres meses.

La disposición propuesta equivale aproximadamente al 0.09% del total de acciones en circulación, indicando una transacción modesta y rutinaria en lugar de una liquidación grande. El declarante certifica no poseer información material adversa no divulgada y confirma el cumplimiento con la Regla 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA)� 내부� 매도� 알리� 위해 Form 144� SEC� 제출했습니다.

  • 판매 예정 주식 �: 64,508 보통�
  • � 시장 가�: $1,928,595.68
  • 예상 매도�: 2025� 7� 30�
  • 중개�: Morgan Stanley Smith Barney LLC, 뉴욕
  • 발행 주식 총수: 74,107,668

주식읶 동일� �(2025� 7� 30�) 직원 주식매수선택� 행사� 취득되었으며, 현금으로 매도� 예정입니�. 지� 3개월� 해당 내부자의 다른 매도 보고� 없었습니�.

이번 매도 예정 주식읶 전체 발행 주식� � 0.09%� 해당하며, 대규모 청산보다� 소규� 일상적인 거래임을 나타냅니�. 제출자는 미공� 중대� 불리� 정보가 없음� 증명하며, Rule 10b5-1 준수를 확인합니�.

Kiniksa Pharmaceuticals International, plc (KNSA) a déposé un Formulaire 144 pour informer la SEC d'une vente d'initié prévue.

  • Actions à vendre : 64 508 actions ordinaires
  • Valeur marchande totale : 1 928 595,68 $
  • Date approximative de la vente : 30/07/2025
  • Intermédiaire : Morgan Stanley Smith Barney LLC, New York
  • Actions en circulation : 74 107 668

Les actions ont été acquises le même jour (30/07/2025) par l'exercice d'options d'achat d'actions des employés dans le cadre d'un plan enregistré et seront vendues contre espèces. Aucune autre vente par cet initié n'a été signalée au cours des trois derniers mois.

La cession proposée représente environ 0,09 % du total des actions en circulation, indiquant une transaction modeste et de taille courante plutôt qu'une liquidation importante. Le déclarant atteste ne pas disposer d'informations défavorables matérielles non divulguées et confirme sa conformité à la règle 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) hat ein Formular 144 eingereicht, um die SEC über einen geplanten Insider-Verkauf zu informieren.

  • Zu verkaufende Aktien: 64.508 Stammaktien
  • Gesamtmarktwert: 1.928.595,68 $
  • Ungefähres Verkaufsdatum: 30.07.2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Ausstehende Aktien: 74.107.668

Die Aktien wurden am selben Tag (30.07.2025) durch Ausübung von Mitarbeiteraktienoptionen im Rahmen eines registrierten Plans erworben und werden gegen Bargeld verkauft. In den letzten drei Monaten wurden keine weiteren Verkäufe dieses Insiders gemeldet.

Die geplante Veräußerung entspricht etwa 0,09 % der insgesamt ausstehenden Aktien und deutet auf eine eher kleine, routinemäßige Transaktion statt auf eine große Liquidation hin. Der Einreicher bestätigt, keine nicht offengelegten wesentlichen nachteiligen Informationen zu besitzen und die Einhaltung von Regel 10b5-1 sicherzustellen.

false000092628200009262822025-07-242025-07-24

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 24, 2025

 

 

ADTRAN Holdings, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41446

87-2164282

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

901 Explorer Boulevard

 

Huntsville, Alabama

 

35806-2807

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 256 963-8000

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, Par Value $0.01 per share

 

ADTN

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

ADTRAN Holdings, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders on July 24, 2025 (the “2025 Annual Meeting”). At the 2025 Annual Meeting, the Company’s stockholders (i) elected seven directors to serve on the board of directors of the Company (the “Board”) for a one-year term expiring at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) and until their successors have been duly elected and qualified (Proposal 1); (ii) approved, on an advisory basis, the compensation of the Company’s named executive officers (Proposal 2); and (iii) ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 (Proposal 3). The voting results for these proposals are presented in the tables below:

Proposal 1 - Election of Directors

 

 

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

Thomas R. Stanton

 

 

50,653,113

 

 

 

4,349,335

 

 

 

56,727

 

 

 

8,570,532

 

H. Fenwick Huss

 

 

51,830,456

 

 

 

3,165,468

 

 

 

63,251

 

 

 

8,570,532

 

Gregory J McCray

 

 

53,384,343

 

 

 

1,571,962

 

 

 

102,870

 

 

 

8,570,532

 

Balan Nair

 

 

41,559,900

 

 

 

13,415,948

 

 

 

83,327

 

 

 

8,570,532

 

Jacqueline H. Rice

 

 

50,984,368

 

 

 

4,012,818

 

 

 

61,989

 

 

 

8,570,532

 

Nikos Theodosopoulos

 

 

53,537,561

 

 

 

1,439,446

 

 

 

82,168

 

 

 

8,570,532

 

Kathryn A. Walker

 

 

54,203,205

 

 

 

770,647

 

 

 

85,323

 

 

 

8,570,532

 

 

Proposal 2 - Advisory Vote Regarding the Compensation of the Company's Named Executive Officers

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

52,151,095

 

 

 

2,748,819

 

 

 

159,261

 

 

 

8,570,532

 

Proposal 3 - Ratification of the Appointment of PricewaterhouseCoopers LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025

For

 

 

Against

 

 

Abstain

 

 

 

61,073,766

 

 

 

2,474,157

 

 

 

81,784

 

 

Item 8.01 Other Events.

On July 29, 2025, the Board set the date for the Company’s 2026 Annual Meeting as May 13, 2026. The meeting will be a virtual meeting conducted by live webcast on the internet. Additional details regarding the 2026 Annual Meeting, including the time and matters to be voted upon, will be set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting to be filed with the U.S. Securities and Exchange Commission (the “SEC”).

As the date of the 2026 Annual Meeting has changed by more than 30 days from the one-year anniversary of the 2025 Annual Meeting, the Company is informing stockholders of this change in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and it is also informing stockholders of the new dates described below for submitting stockholder proposals and other matters.

Pursuant to Rule 14a-8 of the Exchange Act, any stockholder intending to present a proposal for inclusion in the proxy statement for the 2026 Annual Meeting must provide timely written notice of the proposal to us at ADTRAN Holdings, Inc., Attn: Corporate Secretary, 901 Explorer Boulevard, Huntsville, Alabama 35806, along with proof of ownership of our stock in accordance with Rule 14a‑8(b)(2). The Company must receive the proposal by December 1, 2025 for possible inclusion in the proxy statement, which the Board has determined to be a reasonable time before the Company expects to begin to print and send its proxy materials in accordance with Rule 14a-8(e). The December 1, 2025 deadline also applies in determining whether notice of a shareholder proposal is timely for purposes of exercising discretionary voting authority with respect to proxies under Rule 14a-4(c)(1) of the Exchange Act.

Additionally, under the Company’s bylaws, any stockholder of record intending to nominate a candidate for election to the Board or to propose any business at the 2026 Annual Meeting must give timely written notice to us at ADTRAN Holdings, Inc., Attn: Corporate Secretary, 901 Explorer Boulevard, Huntsville, Alabama 35806. A nomination or proposal for the 2026 Annual Meeting will be considered timely if it is received no earlier than January 13, 2026 (the 120th day prior to the 2026 Annual Meeting) and no later than the close of business on February 12, 2026 (the later of the 90th day prior to the 2026 Annual Meeting and the 10th day following the day on which public announcement of the date of the 2026 Annual Meeting is first made). In no event shall the adjournment or postponement of the 2026 Annual Meeting commence a new time period (or extend any time period) for the giving of a stockholder’s notice with respect to a nomination or proposal for the 2026 Annual Meeting. The notice of nomination or proposal, including any notice of a proposal for inclusion in the proxy statement described in the paragraph above, must detail the information specified in the Company’s bylaws and comply with Delaware law and the applicable rules of the SEC. The Company will not entertain any proposals or nominations at the 2026 Annual Meeting that do not meet the requirements set forth in its bylaws. In addition to satisfying the requirements under our bylaws, to comply with the SEC’s universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees at the 2026 Annual Meeting must provide notice to the Company that complies with the informational requirements of Rule 14a-19 under the Exchange Act.


 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit Number

 

Description

104

Cover Page Interactive Data File – the cover page iXBRL tags are embedded within the Inline XBRL document

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ADTRAN Holdings, Inc.

 

 

 

 

Date:

July 30, 2025

By:

/s/ Timothy Santo

 

 

 

Timothy Santo
Senior Vice President of Finance and
Chief Financial Officer

 


FAQ

How many KNSA shares are being sold under this Form 144?

64,508 common shares are slated for sale.

What is the aggregate market value of the planned Kiniksa insider sale?

The filing lists an aggregate value of $1,928,595.68.

When is the approximate sale date for the KNSA shares?

The filer indicates an approximate sale date of 07/30/2025.

What percentage of KNSA's outstanding shares does this sale represent?

The 64,508 shares equal roughly 0.09% of the 74,107,668 shares outstanding.

Were there any other insider sales reported in the past three months?

No. The Form 144 states "Nothing to Report" for the prior three-month period.

How were the shares acquired prior to the sale?

They were obtained via option exercises under a registered plan on 07/30/2025 for cash.
Adtran Inc

NASDAQ:ADTN

ADTN Rankings

ADTN Latest News

ADTN Latest SEC Filings

ADTN Stock Data

701.09M
78.91M
1.4%
84.44%
2.53%
Communication Equipment
Telephone & Telegraph Apparatus
United States
HUNTSVILLE